STOCK TITAN

DiaMedica Therapeutics Inc. (DMAC) Net Income by Year

DMAC

DiaMedica Therapeutics Inc. reported a net loss of $32.8M in fiscal year 2025. This represents a decrease of 34.0% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters DiaMedica Therapeutics Inc. has filed alongside them.

FY2025 annual
Net Income -$32.8M
YoY -34.0%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

DMAC Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-K
Net Income-$32.8M-34.0%-$24.4M-26.1%-$19.4M-41.7%-$13.7M-0.6%-$13.6M-10.6%-$12.3M-15.4%-$10.6M-85.7%-$5.7M-34.6%-$4.3M

DMAC Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$10.1M-31.7%-$10.0M-30.3%N/A-$8.6M-37.4%-$7.7M-50.4%-$7.7M-49.6%N/A-$6.3M-40.3%-$5.1M-14.3%-$5.2M+2.3%N/A-$4.5M-46.2%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More DiaMedica Therapeutics Inc. financials

Frequently Asked Questions

What was DiaMedica Therapeutics Inc.'s net income in fiscal year 2025?

DiaMedica Therapeutics Inc. reported a net loss of $32.8M in fiscal year 2025.

How fast is DiaMedica Therapeutics Inc.'s net income growing?

DiaMedica Therapeutics Inc. (DMAC) net income fell by 34.0% year over year, from -$24.4M to -$32.8M in fiscal year 2025.

How has DiaMedica Therapeutics Inc.'s net income changed over the years?

Across the 9 fiscal years this page covers, DiaMedica Therapeutics Inc. (DMAC) net income went from -$4.3M in fiscal year 2017 to -$32.8M in fiscal year 2025.

DiaMedica Therapeutics Inc. (DMAC) reported -$10.1M in net income in Q2 2026. This represents a decrease of 31.7% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what DiaMedica Therapeutics Inc. (DMAC) reported on that line in every period on record.